penfluridol

Penfluridol is a highly potent, first-generation diphenylbutylpiperidine antipsychotic developed by Janssen Pharmaceutica in 1968. It is primarily indicated for the treatment of chronic schizophrenia and similar psychotic disorders. Penfluridol acts mainly as a long-lasting dopamine D2 receptor antagonist, with additional activity as a T-type calcium channel blocker. Its effects are notable for their extended duration, allowing once-weekly oral dosing. While effective in controlling psychotic symptoms with relatively low sedative properties, it frequently causes extrapyramidal side effects such as akathisia and pseudo-Parkinsonism. Due to its side effect profile and the advent of atypical antipsychotics, its use has declined in recent years[1][5][6].

Brand names

SemapMicefalLongoperidol

Other names

penfluridol